• Aloin Isoforms Selectively Inhibit SARS-CoV-2 PLpro In Vitro

  2026-06-12

  This study identifies aloin A and B as selective inhibitors of the SARS-CoV-2 papain-like protease (PLpro), revealing distinct mechanisms for blocking both proteolytic and deubiquitinating activities in vitro. These findings clarify the molecular interactions targeted by aloin isoforms and differentiate their antiviral potential from other common oral antimicrobial agents.

• Cell Counting Kit-8 (CCK-8) Plus: Practical Workflow Guidanc

  2026-06-11

  Cell Counting Kit-8 (CCK-8) Plus enables rapid, sensitive measurement of cell viability and cytotoxicity for proliferation and drug screening workflows. It should be used for in vitro assays requiring accurate quantification of viable cells, but is not suitable where endpoint lysis or redox interference may occur.

• Brassinolide (A3265): Data-Driven Solutions for Cell Assays

  2026-06-11

  This article addresses real laboratory challenges in cell viability, apoptosis, and metabolic regulation, demonstrating how Brassinolide (SKU A3265) supports reproducible, quantitative research in cancer and diabetes models. Scenario-driven Q&A blocks synthesize peer-reviewed data and validated protocols, guiding biomedical researchers and lab technicians towards reliable outcomes using Brassinolide from APExBIO.

• Sisomicin: Optimizing Aminoglycoside Workflows for Infection

  2026-06-10

  Sisomicin sets a high bar for both Gram-negative and Gram-positive infection modeling, empowering researchers with reproducible protocols and actionable troubleshooting strategies. Learn how to harness its unique activity profile and robust data to streamline antibacterial assays and resistance studies.

• HyperScribe™ Poly (A) Tailing Kit: Precision RNA Polyadenyla

  2026-06-10

  The HyperScribe™ Poly (A) Tailing Kit enables enzymatic addition of poly (A) tails to RNA, enhancing mRNA stability and translation efficiency for advanced gene expression studies. Utilizing E. coli Poly (A) Polymerase, this kit ensures reproducible and efficient in vitro RNA modification for research workflows.

• AR Heterogeneity Defines Distinct CRPC Responses to Enzaluta

  2026-06-09

  The referenced study demonstrates that heterogeneity in androgen receptor (AR) expression within prostate cancer drives differential responses to castration and enzalutamide treatment. By integrating xenograft models, genome engineering, and transcriptomic profiling, the authors map out mechanistic links between AR status and therapy resistance, revealing actionable targets for distinct CRPC subtypes.

• Intra- and Extracellular Dicloxacillin Activity in MSSA Mode

  2026-06-09

  This study rigorously evaluates dicloxacillin’s intra- and extracellular efficacy against methicillin-sensitive Staphylococcus aureus (MSSA), using both in vitro macrophage assays and an in vivo mouse peritonitis model. Key findings reveal that free drug time above MIC is the best predictor of antibiotic efficacy, with implications for optimizing dosing strategies and translational research design.

• Hexetidine (NSC-17764): Optimizing Oral Antimicrobial Assays

  2026-06-08

  Hexetidine (NSC-17764) is a potent, broad-spectrum antibacterial agent for oral infection models, with unique synergy in combination therapies and proven efficacy in biofilm inhibition. Here, we detail robust experimental workflows, troubleshooting strategies, and protocol enhancements to maximize translational impact in dental research.

• BV6 IAP Antagonist: Deep Mechanisms and Translational Insigh

  2026-06-08

  Explore the science behind BV6, a selective IAP antagonist, with a deep dive into its mechanism, translational research value, and practical assay implications. This article uniquely connects advanced apoptosis biology to experimental protocol design.

• Drug Interaction Risks of Oteseconazole: Mechanistic Insight

  2026-06-07

  A 2024 analysis of small molecule drugs approved by the FDA in 2022 highlights the enzyme and transporter-mediated drug-drug interaction (DDI) risks, with a focus on Oteseconazole's mechanistic profile as both an inhibitor and substrate. These findings clarify the clinical relevance of Oteseconazole’s pharmacokinetic interactions and inform safer co-administration practices in polypharmacy settings.

• Caffeine (1,3,7-trimethylpurine-2,6-dione): Precision Tools

  2026-06-06

  Explore caffeine (1,3,7-trimethylpurine-2,6-dione) as a precision research tool for dissecting energy metabolism and cancer cell line inhibition. This article delivers a uniquely integrative analysis, bridging molecular pharmacology with protocol decision-making and cross-domain assay design.

• Q-VD(OMe)-OPh: Precision Caspase Inhibition for Apoptosis As

  2026-06-05

  Q-VD(OMe)-OPh delivers robust, non-toxic caspase inhibition, enabling reproducible apoptosis assays and advanced mechanistic studies in cancer and neuroprotection. Its superior selectivity and workflow compatibility distinguish it from legacy inhibitors, streamlining both routine and complex experimental setups.

• LGK-974: Translating PORCN Inhibition into Wnt Cancer Therap

  2026-06-05

  This thought-leadership article provides translational researchers with a strategic, mechanistic, and evidence-based guide to leveraging LGK-974—a potent and highly specific PORCN inhibitor—for advancing Wnt-driven cancer therapy. Integrating evolutionary insight, experimental best practices, and comparative analysis, it charts a path from fundamental Wnt pathway biology to impactful translational applications in models such as pancreatic cancer with RNF43 mutations.

• 3-Deazaneplanocin (DZNep): Applied Workflows for Cancer Rese

  2026-06-04

  3-Deazaneplanocin (DZNep) enables precise epigenetic modulation, helping researchers dissect cancer stem cell biology and apoptosis pathways. This article provides actionable protocols, advanced troubleshooting, and insights into leveraging DZNep for reproducible oncology and metabolic disease studies.

• ZK53: Redefining Human ClpP Activation for Cancer Mitochondr

  2026-06-04

  Explore the profound impact of ZK53, a potent human mitochondrial serine protease ClpP activator, on cancer research. This article uniquely dissects ZK53’s mechanistic selectivity, translational in vivo data, and practical protocol insights for advanced mitochondrial dysfunction studies.

453 records 15/31 page Previous Next First page 上5页 1112131415 下5页 Last page